Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 15;18(7):e0012323.
doi: 10.1371/journal.pntd.0012323. eCollection 2024 Jul.

American Cutaneous Leishmaniasis: Imported cases in Berlin 2000-2023

Affiliations

American Cutaneous Leishmaniasis: Imported cases in Berlin 2000-2023

Andreas K Lindner et al. PLoS Negl Trop Dis. .

Abstract

Background: American Cutaneous Leishmaniasis (ACL) shows variable response to therapy, but data on species-specific treatment efficacy is scarce. We describe the clinical characteristics and outcome of patients with ACL imported to a tertiary centre in Germany and determine whether species-specific therapy according to the 2014 "LeishMan" group recommendations is associated with cure.

Methods: A retrospective chart review was conducted at the Charité Institute of International Health in Berlin. We analysed data on PCR-confirmed ACL cases collected between 2000 and 2023. Systemic therapy included liposomal amphotericin B, miltefosine, pentavalent antimony, ketoconazole or itraconazole. Localized therapy included perilesional pentavalent antimony or paromomycin ointment. Cure was defined as re-epithelialization of ulcers or disappearance of papular-nodular lesions after 3 months of treatment. Logistic regression models were used to quantify the effect of species-specific systemic therapy on the outcome.

Results: 75 cases were analysed. Most patients were male (62%), median age was 35 years, no patient had a history of immunosuppression. The most common reason for travel was tourism (60%), the most common destination was Costa Rica (28%), the median duration of illness was 8 weeks, and most patients presented with ulcers (87%). Lesions were complex in 43%. The most common Leishmania (L.) species was L. braziliensis (28%), followed by L. panamensis (21%). 51/73 (70%) patients were cured after initial therapy and 17/21 (81%) after secondary therapy. Cure after systemic therapy was more frequent when species-specific treatment recommendations were followed (33/45; 73%), compared to when not followed, (6/17; 35%, P = 0.008). This association was independent of age, sex, previous therapy, complex lesions, and Leishmania species (adjusted OR, 5.06; 95% CI, 1.22-24.16).

Conclusions: ACL is a rare, imported disease in Germany. Complex lesions were common, challenging successful therapy. This study highlights the importance of identifying the parasite species and suggests that a species-specific approach to treatment leads to better outcomes.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Geographical distribution according to the country of exposure and Leishmania species identified of the ACL cases imported to Berlin from 2000–2023.
The map was created with the software program R using the following source of the basemap shapefile: Massicotte P, South A (2024). rnaturalearth: World Map Data from Natural Earth. R package version 1.0.1.9000, https://github.com/ropensci/rnaturalearth, https://docs.ropensci.org/rnaturalearthhires/, https://docs.ropensci.org/rnaturalearth/.

References

    1. Blum J, Buffet P, Visser L, Harms G, Bailey MS, Caumes E, et al. LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014. J Travel Med. 2014;21(2):116–29. doi: 10.1111/jtm.12089 - DOI - PubMed
    1. Madusanka RK, Silva H, Karunaweera ND. Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review. Infect Dis Ther. 2022;11(2):695–711. doi: 10.1007/s40121-022-00602-2 - DOI - PMC - PubMed
    1. Fahrion A, Gasimov E, Joseph S, Grout L, Allan M, Postigo JR. Surveillance of leishmaniasis in the WHO European Region and Global leishmaniasis surveillance update, 1998–2016. Rev Epidemiol Sante Publique. 2018;66(40):S394.
    1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5). doi: 10.1371/journal.pone.0035671 - DOI - PMC - PubMed
    1. World Health Organization. Leishmaniasis [Internet]. 2023. [cited 2024 Jan 5]. Available from: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis

MeSH terms

LinkOut - more resources